Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/immunology-and-immunotherapy-of-chronic-myeloid-leukemia-8L6vG4DlGp
References (80)
-
K. Ohyashiki, S. Katagiri, T. Tauchi, J. Ohyashiki, Y. Maeda, I. Matsumura, T. Kyo (2012)
Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinibBritish Journal of Haematology, 157
-
G Saglio, DW Kim, S Issaragrisil (2010)
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med, 362
-
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.The New England journal of medicine, 355 23
-
H. Fujiwara, F. Ouriaghli, M. Grube, D. Price, K. Rezvani, E. Gostick, G. Sconocchia, J. Melenhorst, N. Hensel, D. Douek, A., J. Barrett (2004)
Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.Blood, 103 8
-
T. Uchiyama, Naoya Sato, M. Narita, A. Yamahira, Minami Iwabuchi, T. Furukawa, H. Sone, Masuhiro Takahashi (2013)
Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro studyHematological Oncology, 31
-
A. Kreutzman, V. Juvonen, V. Kairisto, M. Ekblom, L. Stenke, R. Seggewiss, K. Porkka, S. Mustjoki (2010)
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.Blood, 116 5
-
H. Jørgensen, E. Allan, N. Jordanides, J. Mountford, T. Holyoake (2007)
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.Blood, 109 9
-
J. Greiner, M. Ringhoffer, M. Taniguchi, A. Schmitt, Dieter Kirchner, G. Krähn, V. Heilmann, J. Gschwend, L. Bergmann, H. Döhner, M. Schmitt (2002)
Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.Experimental hematology, 30 9
-
M. Horowitz, R. Gale, P. Sondel, J. Goldman, J. Kersey, H. Kolb, A. Rimm, O. Ringdén, C. Rozman, B. Speck (1990)
Graft-versus-leukemia reactions after bone marrow transplantation.Blood, 75 3
-
L. Christiansson, Stina Söderlund, E. Svensson, S. Mustjoki, M. Bengtsson, B. Simonsson, U. Olsson‐Strömberg, A. Loskog (2013)
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid LeukemiaPLoS ONE, 8
-
A. Burchert, Martin Müller, P. Kostrewa, P. Erben, T. Bostel, S. Liebler, R. Hehlmann, A. Neubauer, A. Hochhaus (2010)
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 8
-
A. Schade, G. Schieven, R. Townsend, A. Jankowska, Vojkan Susulic, R. Zhang, H. Szpurka, J. Maciejewski (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.Blood, 111 3
-
M. Järås, P. Johnels, N. Hansen, H. Ågerstam, P. Tsapogas, M. Rissler, C. Lassen, T. Olofsson, O. Bjerrum, J. Richter, T. Fioretos (2010)
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory proteinProceedings of the National Academy of Sciences, 107
-
J. Pinilla-Ibarz, T. Korontsvit, V. Zakhaleva, Wendy Roberts, D. Scheinberg (2005)
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.Haematologica, 90 10
-
M. Šmahel (2011)
Antigens in chronic myeloid leukemia: implications for vaccine developmentCancer Immunology, Immunotherapy, 60
-
M. Bocchia, Sara Gentili, E. Abruzzese, Albertina Fanelli, Francesco Iuliano, Antonio Tabilio, M. Amabile, Francesco Forconi, A. Gozzetti, D. Raspadori, Sergio Amadori, F. Lauria (2005)
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trialThe Lancet, 365
-
A. Kreutzman, T. Jaatinen, D. Greco, Emmi Vakkila, J. Richter, M. Ekblom, H. Hjorth-Hansen, L. Stenke, T. Melo, R. Paquette, R. Seggewiss-Bernhardt, A. Guerci-Bresler, A. Talbot, J. Cayuela, F. Mahon, K. Porkka, J. Lipton, J. Partanen, P. Rousselot, S. Mustjoki (2012)
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.Experimental hematology, 40 11
-
C. Chen, Steffen Koschmieder, Linda Kerstiens, M. Schemionek, B. Altvater, S. Pscherer, Joachim Gerss, Holden Maecker, Wolfgang Berdel, H. Juergens, Peter Lee, C. Rossig (2012)
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive miceLeukemia, 26
-
G. Nasa, G. Caocci, R. Littera, S. Atzeni, A. Vacca, O. Mulas, M. Langiu, M. Greco, S. Orrù, N. Orrú, Andrea Floris, C. Carcassi (2013)
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.Experimental hematology, 41 5
-
B. Simonsson, T. Gedde-Dahl, B. Markevärn, K. Remes, J. Stentoft, A. Almqvist, M. Björeman, M. Flogegård, Perttu Koskenvesa, A. Lindblom, C. Malm, S. Mustjoki, K. Myhr-Eriksson, Lotta Ohm, A. Räsänen, M. Sinisalo, A. Själander, U. Strömberg, O. Bjerrum, H. Ehrencrona, F. Gruber, V. Kairisto, K. Olsson, F. Sandin, A. Nagler, J. Nielsen, H. Hjorth-Hansen, K. Porkka (2011)
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.Blood, 118 12
-
M. Gordon (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaYearbook of Oncology, 2010
-
Y. Hayashi, H. Nakamae, T. Katayama, T. Nakane, H. Koh, M. Nakamae, A. Hirose, K. Hagihara, Y. Terada, Y. Nakao, M. Hino (2012)
Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinibLeukemia & Lymphoma, 53
-
J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed, M. Burke, A. Caldwell, S. Kronenberg, B. Agunwamba, Xiaoling Zhang, I. Lowy, H. Inzunza, W. Feely, C. Horak, Q. Hong, A. Korman, J. Wigginton, A. Gupta, M. Sznol (2013)
Nivolumab plus ipilimumab in advanced melanoma.The New England journal of medicine, 369 2
-
S. Mustjoki, M. Ekblom, T. Arstila, I. Dybedal, PK Burnette, Felix Garzon, T. Gedde-Dahl, Sari Hernesniemi, H. Hjorth-Hansen, M. Hoglund, V. Juvonen, V. Kairisto, P. Kovanen, A. Kreutzman, T. Laurinolli, J. Liesveld, R. Paquette, J. Pinilla, A. Rauhala, N. Shah, B. Simonsson, M. Sinisalo, J. Steegmann, L. Stenke, J. Vakkila, K. Porkka (2008)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyLeukemia, 23
-
A. Hochhaus, M. Baccarani, M. Deininger, J. Apperley, J. Lipton, S. Goldberg, S. Corm, N. Shah, F. Cervantes, R. Silver, D. Niederwieser, R. Stone, H. Dombret, R. Larson, L. Roy, T. Hughes, M. Müller, R. Ezzeddine, A. Countouriotis, H. Kantarjian (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia, 22
-
T. Dao, Su Yan, N. Veomett, D. Pankov, Liang Zhou, T. Korontsvit, A. Scott, Joseph Whitten, P. Maslak, E. Casey, Taochao Tan, Hong Liu, V. Zakhaleva, Michael Curcio, E. Doubrovina, R. O'reilly, Cheng Liu, D. Scheinberg (2013)
Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human AntibodyScience Translational Medicine, 5
-
A. Kreutzman, A. Kreutzman, K. Porkka, S. Mustjoki (2013)
Immunomodulatory Effects of Tyrosine Kinase Inhibitors -
Y. Hailemichael, Zhimin Dai, Nina Jaffarzad, Y. Ye, M. Medina, Xue Huang, S. Dorta-Estremera, N. Greeley, G. Nitti, W. Peng, Chengwen Liu, Y. Lou, Zhiqiang Wang, Wencai Ma, B. Rabinovich, K. Schluns, R. Davis, P. Hwu, W. Overwijk (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletionNature medicine, 19
-
Ghofran Qudaihi, C. Lehé, A. Dickinson, Khaled Eltayeb, W. Rasheed, N. Chaudhri, M. Aljurf, S. Dermime (2010)
Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes.Hematology/oncology and stem cell therapy, 3 1
-
P. Rohoň, K. Porkka, S. Mustjoki (2010)
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapyEuropean Journal of Haematology, 85
-
P. Maslak, T. Dao, L. Krug, S. Chanel, T. Korontsvit, V. Zakhaleva, Ronghua Zhang, J. Wolchok, Jianda Yuan, J. Pinilla-Ibarz, E. Berman, M. Weiss, J. Jurcic, M. Frattini, D. Scheinberg (2010)
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.Blood, 116 2
-
Mette Ilander, Perttu Koskenvesa, Sari Hernesniemi, T. Lion, K. Porkka, S. Mustjoki (2014)
Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapyLeukemia & Lymphoma, 55
-
M. Askmyr, H. Ågerstam, N. Hansen, S. Gordon, Alex Arvanitakis, M. Rissler, G. Juliusson, J. Richter, M. Järås, T. Fioretos (2013)
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.Blood, 121 18
-
A. Kreutzman, P. Rohoň, E. Faber, K. Indrák, V. Juvonen, V. Kairisto, J. Voglová, M. Sinisalo, E. Flochová, J. Vakkila, Petteri Arstila, K. Porkka, S. Mustjoki (2011)
Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte ProfilePLoS ONE, 6
-
D. Marin, I. Gabriel, S. Ahmad, L. Foroni, H. Lavallade, R. Clark, S. O’Brien, R. Sergeant, C. Hedgley, D. Milojkovic, J. Khorashad, M. Bua, A. Alsuliman, A. Khoder, K. Stringaris, N. Cooper, J. Davis, J. Goldman, J. Apperley, K. Rezvani (2012)
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinibLeukemia, 26
-
J. Cortes, Dong-Wook Kim, H. Kantarjian, T. Brümmendorf, I. Dyagil, L. Griškevičius, H. Malhotra, C. Powell, K. Gogat, A. Countouriotis, C. Gambacorti-Passerini (2012)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
-
Hideo Tanaka, Shizuka Nakashima, M. Usuda (2012)
Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patientsInternational Journal of Hematology, 96
-
F. Castro, P. Palma, F. Morais, B. Simões, P. Carvalho, S. Ismael, Carmen Voltarelli, Júlio Morais (2003)
Immunological Effects of Interferon-alpha on Chronic Myelogenous LeukemiaLeukemia & Lymphoma, 44
-
H Kantarjian, NP Shah, A Hochhaus (2010)
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med, 362
-
T. Ochi, H. Fujiwara, K. Suemori, T. Azuma, Y. Yakushijin, T. Hato, K. Kuzushima, M. Yasukawa (2008)
Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.Blood, 113 1
-
U. Keilholz, A. Letsch, A. Busse, A. Asemissen, S. Bauer, I. Blau, W. Hofmann, L. Uharek, E. Thiel, C. Scheibenbogen (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.Blood, 113 26
-
E. Bachy, J. Bernaud, P. Roy, D. Rigal, F. Nicolini (2011)
Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylateBritish Journal of Haematology, 153
-
S. Mustjoki, Kaisa Auvinen, A. Kreutzman, Rousselot, Sari Hernesniemi, T. Melo, Lahesmaa-Korpinen Am, S. Hautaniemi, Stéphane Bouchet, Mathieu Molimard, Richard Smykla, Frank Lee, J. Vakkila, S. Jalkanen, Marko Salmi, K. Porkka (2013)
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapyLeukemia, 27
-
H. Kantarjian, F. Giles, N. Gattermann, K. Bhalla, G. Alimena, F. Palandri, G. Ossenkoppele, F. Nicolini, S. O’Brien, M. Litzow, R. Bhatia, F. Cervantes, A. Haque, Y. Shou, D. Resta, A. Weitzman, A. Hochhaus, P. Coutre (2007)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.Blood, 110 10
-
R. Lemoli, Valentina Salvestrini, E. Bianchi, F. Bertolini, M. Fogli, M. Amabile, A. Tafuri, S. Salati, R. Zini, N. Testoni, C. Rabascio, L. Rossi, I. Martìn‐padura, F. Castagnetti, Paola Marighetti, G. Martinelli, M. Baccarani, S. Ferrari, R. Manfredini (2008)
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.Blood, 114 25
-
J. Kessler, S. Bres-Vloemans, P. Veelen, A. Ru, I. Huijbers, M. Camps, A. Mulder, R. Offringa, J. Drijfhout, O. Leeksma, F. Ossendorp, C. Melief (2006)
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopesLeukemia, 20
-
Ann Cai, D. Keskin, D. DeLuca, Anselmo Alonso, Wandi Zhang, G. Zhang, Naa Hammond, V. Nardi, R. Stone, D. Neuberg, J. Sidney, V. Brusic, Catherine Wu (2012)
Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML PatientsClinical Cancer Research, 18
-
M. Copland, A. Hamilton, L. Elrick, J. Baird, E. Allan, N. Jordanides, M. Barow, J. Mountford, T. Holyoake (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.Blood, 107 11
-
J. Molldrem, E. Clave, Y. Jiang, D. Mavroudis, A. Raptis, N. Hensel, V. Agarwala, A. Barrett (1997)
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.Blood, 90 7
-
M. Kijima, N. Gardiol, W. Held (2011)
Natural Killer Cell Mediated Missing-Self Recognition Can Protect Mice from Primary Chronic Myeloid Leukemia In VivoPLoS ONE, 6
-
C. Preudhomme, J. Guilhot, F. Nicolini, A. Guerci-Bresler, F. Rigal-huguet, F. Maloisel, V. Coiteux, M. Gardembas, C. Berthou, A. Vekhoff, D. Réa, E. Jourdan, C. Allard, A. Delmer, P. Rousselot, L. Legros, M. Berger, S. Corm, G. Étienne, C. Roche-Lestienne, V. Eclache, F. Mahon, F. Guilhot (2010)
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.The New England journal of medicine, 363 26
-
K. Rezvani, A. Yong, S. Mielke, B. Savani, Laura Musse, J. Superata, Behnam Jafarpour, C. Boss, A. Barrett (2007)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.Blood, 111 1
-
D. Ross, S. Branford, J. Seymour, A. Schwarer, C. Arthur, D. Yeung, P. Dang, J. Goyne, C. Slader, R. Filshie, A. Mills, J. Melo, D. White, A. Grigg, T. Hughes (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.Blood, 122 4
-
S. Graham, H. Jørgensen, E. Allan, C. Pearson, M. Alcorn, L. Richmond, T. Holyoake (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.Blood, 99 1
-
H. Itonaga, H. Tsushima, T. Hata, E. Matsuo, D. Imanishi, Y. Imaizumi, Y. Kawaguchi, T. Fukushima, Y. Doi, Sayaka Mori, S. Kamihira, M. Tomonaga, Y. Miyazaki (2012)
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfaInternational Journal of Hematology, 95
-
Jonathan Gerber, L. Qin, J. Kowalski, B. Smith, C. Griffin, M. Vala, M. Collector, B. Perkins, M. Zahurak, W. Matsui, C. Gocke, S. Sharkis, H. Levitsky, Richard Jones (2011)
Characterization of chronic myeloid leukemia stem cellsAmerican Journal of Hematology, 86
-
Graham Pawelec, P. Silva, Heiner Max, Hubert Kalbacher, Helmuth Schmidt, Øystein Bruserud, Ullrich Zügel, Wolfgang Baier, A. Rehbein, Heike Pohlat (1995)
Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.Leukemia & lymphoma, 18 5-6
-
S. Mustjoki, J. Richter, Gisela Barbany, H. Ehrencrona, T. Fioretos, T. Gedde-Dahl, B. Gjertsen, R. Hovland, Sari Hernesniemi, Dag Josefsen, Perttu Koskenvesa, I. Dybedal, B. Markevärn, Tobias Olofsson, U. Olsson‐Strömberg, Katrin Rapakko, Sarah Thunberg, L. Stenke, B. Simonsson, K. Porkka, H. Hjorth-Hansen (2013)
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patientsLeukemia, 27
-
Julia Salih, J. Hilpert, T. Placke, F. Grünebach, A. Steinle, H. Salih, M. Krusch (2010)
The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivityInternational Journal of Cancer, 127
-
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, J. Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)
Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine, 363 8
-
R. Seggewiss, K. Loré, E. Greiner, M. Magnússon, D. Price, D. Douek, C. Dunbar, A. Wiestner (2005)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.Blood, 105 6
-
M. Casucci, S. Perna, L. Falcone, B. Camisa, Z. Magnani, M. Bernardi, A. Crotta, C. Tresoldi, K. Fleischhauer, M. Ponzoni, S. Gregori, F. Cappio, F. Ciceri, C. Bordignon, A. Cignetti, A. Bondanza, C. Bonini (2013)
Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene.Molecular therapy : the journal of the American Society of Gene Therapy, 21 2
-
A. Cornelison, M. Welch, C. Koller, E. Jabbour (2011)
Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.Clinical lymphoma, myeloma & leukemia, 11 Suppl 1
-
M. Gordon (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaYearbook of Oncology, 2010
-
Sara Ali, R. Sergeant, S. O’Brien, L. Foroni, C. Hedgley, G. Gerrard, D. Milojkovic, K. Stringaris, A. Khoder, A. Alsuliman, M. Gilleece, I. Gabriel, N. Cooper, J. Goldman, J. Apperley, R. Clark, D. Marin, K. Rezvani (2012)
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.Blood, 120 3
-
Hai-tao Zheng, Yu Chen, Shaohua Chen, Yuzhe Niu, Li-jian Yang, Bo Li, Yuhong Lu, S. Geng, X. Du, Yangqiu Li (2011)
Expression and distribution of PPP2R5C gene in leukemiaJournal of Hematology & Oncology, 4
-
L. Ruggeri, M. Capanni, M. Casucci, I. Volpi, A. Tosti, K. Perruccio, E. Urbani, R. Negrin, M. Martelli, A. Velardi (1999)
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.Blood, 94 1
-
T. O'hare, W. Shakespeare, Xiaotian Zhu, C. Eide, V. Rivera, Frank Wang, Lauren Adrian, T. Zhou, Wei-sheng Huang, Qihong Xu, C. Metcalf, J. Tyner, M. Loriaux, A. Corbin, Scott Wardwell, Y. Ning, J. Keats, Yihan Wang, R. Sundaramoorthi, Mathew Thomas, Dong Zhou, Joseph Snodgrass, L. Commodore, T. Sawyer, D. Dalgarno, M. Deininger, B. Druker, T. Clackson (2009)
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.Cancer cell, 16 5
-
K. Cathcart, J. Pinilla-Ibarz, T. Korontsvit, J. Schwartz, V. Zakhaleva, E. Papadopoulos, D. Scheinberg (2004)
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.Blood, 103 3
-
H. Lavallade, A. Khoder, M. Hart, Anushruti Sarvaria, T. Sekine, A. Alsuliman, S. Mielke, A. Bazeos, K. Stringaris, Sara Ali, D. Milojkovic, L. Foroni, A. Chaidos, N. Cooper, I. Gabriel, J. Apperley, S. Belsey, R. Flanagan, J. Goldman, E. Shpall, P. Kelleher, D. Marin, K. Rezvani (2013)
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.Blood, 122 2
-
F. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Étienne, J. Reiffers, P. Rousselot (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.The Lancet. Oncology, 11 11
-
N. Hassold, K. Seystahl, Kristina Kempf, D. Urlaub, Michael Zekl, H. Einsele, C. Watzl, J. Wischhusen, R. Seggewiss-Bernhardt (2012)
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinibInternational Journal of Cancer, 131
-
M. Mori, B. Druker, M. O'Dwyer, M. Mauro, Carolyn Blasdel, M. Farnsworth, Gwen Kurilik (2011)
patients treated with imatinib mesylate prognostic factors for hematologic relapse of chronic phase CML Clonal evolution and lack of cytogenetic response are adverse -
A. Kreutzman, K. Ladell, C. Koechel, E. Gostick, M. Ekblom, L. Stenke, T. Melo, H. Einsele, K. Porkka, D. Price, S. Mustjoki, R. Seggewiss (2011)
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivationLeukemia, 25
-
R. Bhatia, Melissa Holtz, N. Niu, R. Gray, D. Snyder, C. Sawyers, D. Arber, M. Slovak, S. Forman (2003)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.Blood, 101 12
-
Izuru Mizoguchi, T. Yoshimoto, S. Katagiri, J. Mizuguchi, T. Tauchi, Y. Kimura, K. Inokuchi, J. Ohyashiki, K. Ohyashiki (2013)
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinibCancer Science, 104
-
R. Weichsel, Carolin Dix, L. Wooldridge, Matthew Clement, A. Fenton-May, A. Sewell, J. Zezula, E. Greiner, E. Gostick, D. Price, H. Einsele, R. Seggewiss (2008)
Profound Inhibition of Antigen-Specific T-Cell Effector Functions by DasatinibClinical Cancer Research, 14
-
Aur Marabelle, H. Kohrt, R. Levy, A. Myers, C. Cummings, D. DeRyckere, H. Earp, D. Graham, S. Bates, R. Sullivan, P. LoRusso, K. Flaherty, Mei Li, M. Kwong, B. Neyns, James Yang, P. Ott, F. Hodi, C. Robert, L. Kwong, M. Davies, K. Sheppard, G. McArthur, S. Schoppmann, U. Vinatzer, N. Popitsch, Martina Mittlb, S. Liebmann-Reindl, G. Jomrich, B. Streubel, P. Birner (2013)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma PatientsClinical Cancer Research, 19
-
J. Pinilla-Ibarz, B. Shah, J. Dubovsky (2009)
The biological basis for immunotherapy in patients with chronic myelogenous leukemia.Cancer control : journal of the Moffitt Cancer Center, 16 2
-
A. Rossignol, Anaïs Levescot, F. Jacomet, A. Robin, S. Basbous, C. Giraud, L. Roy, F. Guilhot, A. Turhan, A. Barra, A. Herbelin, J. Gombert (2012)
Evidence for BCR‐ABL‐dependent dysfunctions of iNKT cells from chronic myeloid leukemia patientsEuropean Journal of Immunology, 42
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0190-1
- pmid
- 24390549
- Publisher site
- See Article on Publisher Site
Abstract
Chronic myeloid leukemia (CML) is a clonal bone marrow stem cell neoplasia known to be responsive to immunotherapy. Despite the success of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 oncokinase, patients are not considered to be cured with the current therapy modalities. However, there have been recent advancements in understanding the immunobiology of the disease (such as tumor specific antigens and immunostimulatory agents), and this may lead to the development of novel, curative treatment strategies. Already there are promising results showing that a small proportion of CML patients are able to discontinue the therapy although they have a minimal amount of residual leukemia cells left. This implies that the immune system is able to restrain the tumor cell expansion. In this review, we aim to give a brief update of the novel aspects of the immune system in CML patients and of the developing strategies for controlling CML by the means of immunotherapy.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Jan 5, 2014